Hallucinations during methylphenidate therapy

Neurology

Volumn 63, Issue 4, 2004, Pages 753-754

  Gross Tsur, Varda ^a   Joseph, Adina ^a   Shalev, Ruth S ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; CASE REPORT; CHILD; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; MALE; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; VISUAL HALLUCINATION;

EID: 4143121081     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000134656.93147.F1     Document Type: Article

References (6)

1. Wilens T, Pelham W, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003;42:424-433.
2. Young JG. Methylphenidate-induced hallucinosis: case histories and possible mechanisms of action. J Dev Behav Pediatr 1981;2:35-38.
3. Klein-Schwartz W, McGrath J. Poison centers' experience with methylphenidate abuse in pre-teens and adolescents. J Am Acad Child Adolesc Psychiatry 2003;42:288-294.
4. Martinez D, Slifstein M, Broft A, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003;23:285-300.
5. Hall W, Hando J, Darke S, Ross J. Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction 1996;91:81-87.
6. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 2004;61:134-142.